Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

BACKGROUND: The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, r...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Cancer
Glavni autori: Striefler, Jana Käthe, Brandes, Franziska, Baur, Alexander, Pfitzner, Berit Maria, Kaul, David, Rau, Daniel, Dörr, Anne, Schmiester, Maren, Koulaxouzidis, Georgios, Bullinger, Lars, Märdian, Sven, Flörcken, Anne
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988236/
https://ncbi.nlm.nih.gov/pubmed/31996176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6551-y
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items